stoxline Quote Chart Rank Option Currency Glossary
Ligand Pharmaceuticals Incorporated (LGND)
97.31  0.64 (0.66%)    07-16 11:37
Open: 97.94
High: 98.63
Volume: 20,759
Pre. Close: 96.67
Low: 95.61
Market Cap: 1,748(M)
Technical analysis
2024-07-16 11:21:00 AM
Short term     
Mid term     
Targets 6-month :  117.6 1-year :  137.36
Resists First :  100.69 Second :  117.6
Pivot price 88.46
Supports First :  86.31 Second :  77.43
MAs MA(5) :  97.66 MA(20) :  86.36
MA(100) :  79.45 MA(250) :  70.45
MACD MACD :  4.2 Signal :  2.6
%K %D K(14,3) :  88.4 D(3) :  91
RSI RSI(14): 71.3
52-week High :  100.69 Low :  49.24
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LGND ] has closed below upper band by 17.1%. Bollinger Bands are 105.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 100.08 - 100.59 100.59 - 100.91
Low: 94.7 - 95.36 95.36 - 95.78
Close: 95.72 - 96.72 96.72 - 97.36
Company Description

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

Headline News

Fri, 12 Jul 2024
Where are the Opportunities in (LGND) - Stock Traders Daily

Thu, 11 Jul 2024
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High on Analyst Upgrade - Defense World

Wed, 10 Jul 2024
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High After Analyst Upgrade - MarketBeat

Wed, 10 Jul 2024
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Nordea Investment Management AB - Defense World

Mon, 08 Jul 2024
Ligand to buy APEIRON Biologics for $100M, ups 2024 revenue outlook (NASDAQ:LGND) - Seeking Alpha

Mon, 08 Jul 2024
Ligand to Acquire APEIRON Biologics AG for $100 Million - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 18 (M)
Shares Float 18 (M)
Held by Insiders 2.3 (%)
Held by Institutions 98 (%)
Shares Short 937 (K)
Shares Short P.Month 859 (K)
Stock Financials
EPS 5.34
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 45
Profit Margin 81.4 %
Operating Margin 9.6 %
Return on Assets (ttm) -0.2 %
Return on Equity (ttm) 13.2 %
Qtrly Rev. Growth -29.7 %
Gross Profit (p.s.) 0
Sales Per Share 6.58
EBITDA (p.s.) 1.88
Qtrly Earnings Growth 103.1 %
Operating Cash Flow 34 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio 18.3
PEG Ratio 0.8
Price to Book value 2.17
Price to Sales 14.86
Price to Cash Flow 51.19
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android